No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Offered ADSs or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered ADSs, whether to facilitate the sale or resale of the Offered ADSs or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 3 contracts
Samples: Underwriting Agreement (I-Mab), Underwriting Agreement (Avadel Pharmaceuticals PLC), Underwriting Agreement (I-Mab)
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the The Company nor any of its subsidiaries has not taken, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Offered ADSs or of Ordinary Shares or any other “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered ADSs, whether to facilitate the sale or resale of the Offered ADSs ADSs, the Ordinary Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 3 contracts
Samples: Underwriting Agreement (Luxfer Holdings PLC), Underwriting Agreement (Celsus Therapeutics Plc.), Underwriting Agreement (Luxfer Holdings PLC)
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, without giving effect to any activities by the Underwriters, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of the Offered ADSs or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered ADSs, whether to facilitate the sale or resale of the Offered ADSs or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 2 contracts
Samples: Underwriting Agreement (Argo Blockchain PLC), Underwriting Agreement (Argo Blockchain PLC)
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that might would reasonably be expected to cause or result in stabilization or manipulation of the price of the Offered ADSs or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered ADSs, whether to facilitate the sale or resale of the Offered ADSs or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 2 contracts
Samples: Underwriting Agreement (Connect Biopharma Holdings LTD), Underwriting Agreement (Nightstar Therapeutics LTD)
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries and consolidated affiliated entities or any of their respective directors, officers or affiliates has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Offered ADSs or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered ADSs, whether to facilitate the sale or resale of the Offered ADSs or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 1 contract
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that might would reasonably be expected to cause or result in stabilization or manipulation of the price of the Offered ADSs or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered ADSs, whether to facilitate the sale or resale of the Offered ADSs or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 1 contract
Samples: Underwriting Agreement (Stealth BioTherapeutics Corp)
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries or any of their respective directors, officers or affiliates has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Offered ADSs or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered ADSs, whether to facilitate the sale or resale of the Offered ADSs or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 1 contract
Samples: Underwriting Agreement (Yintech Investment Holdings LTD)
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither None of the Company nor any of its subsidiaries Selling Shareholders has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Offered ADSs or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered ADSs, whether to facilitate the sale or resale of the Offered ADSs or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 1 contract
Samples: Underwriting Agreement (I-Mab)
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Offered ADSs or Common Shares or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered ADSsADSs or Common Shares, whether to facilitate the sale or resale of the Offered ADSs or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 1 contract
No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the The Company nor any of its subsidiaries has not taken, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Offered ADSs ADSs, the Ordinary Shares or of any other “reference security” (as defined in Rule 100 of Regulation M under the Exchange 1934 Act (“Regulation M”)) with respect to the Offered ADSs, whether to facilitate the sale or resale of the Offered Shares or the Offered ADSs or otherwise, and has taken no action which would directly or indirectly violate Regulation M.
Appears in 1 contract
Samples: Underwriting Agreement (Mindray Medical International LTD)